Inflammatory Bowel Disease
Infliximab levels above 6.9 mg/L at week 14 predict sustained remission in pediatric IBD
Infliximab concentrations above 6.9 mg/L at 14 weeks after initiation of treatment predicted sustained remission between 26 and 52 weeks in children with inflammatory bowel disease, according to researchers in the Netherlands.
Prebiotic inulin causes ‘beneficial changes’ in microbiome of children with IBD
LAS VEGAS — Supplementation with prebiotic oligofructose-enriched inulin resulted in short-term microbiome changes as early as 4 weeks among children with inflammatory bowel disease, according to a presenter at Crohn’s & Colitis Congress.
Depression ‘stronger predictor’ of fatigue in IBD vs. self-reported disease activity
LAS VEGAS — Depression strongly correlated with most fatigue subtypes, especially mental fatigue, among patients with inflammatory bowel disease, according to a presentation at the Crohn’s & Colitis Congress.
Insurance-mandated barriers linked to negative clinical outcomes in IBD care
LAS VEGAS — Medication denials, forced medication switches and prior authorizations were among insurance-mandated barriers associated with negative clinical outcomes among patients with inflammatory bowel disease, according to data.
Anti-TNF therapy significantly improves growth disturbances in pediatric Crohn’s
LAS VEGAS — Although a substantial proportion of children with Crohn’s disease had growth disturbances at initiation of anti-tumor necrosis factor therapy, “significant improvement” was noted up to 24 months after treatment, data showed.
Conversion initiative gives ‘significant’ boost to Remicade biosimilar use
An initiative to switch clinically stable patients from Remicade to a biosimilar significantly increased biosimilar use in rheumatology and gastroenterology clinics within the University of North Carolina health system, according to data.
Dietitians have ‘very diverse, rich roles,’ add value to the IBD care team
LAS VEGAS — Partnering with a dietitian who specializes in inflammatory bowel disease can augment patient care through nutritional assessment, dietary counseling and perioperative optimization, according to a presenter.
The average cost of inflammatory bowel disease care neared $16,000 per patient in 2019
LAS VEGAS — The cost associated with treating inflammatory bowel disease “significantly increased” from 2009 to 2019 and was largely attributed to the annual cost of biologics, a presenter reported at the Crohn’s & Colitis Congress.
Atopic dermatitis may be linked to inflammatory bowel disease
An association between moderate to severe atopic dermatitis and inflammatory bowel disease suggests a multidisciplinary approach to AD may be necessary, according to a study.
Foreign-born patients with IBD have ‘milder’ disease, later onset, regardless of race
Inflammatory bowel disease phenotype and behavior vary by race and immigration status, with foreign-born patients of all races experiencing less severe disease and later onset than those born in the U.S., researchers reported.